Background: Optimal prevention of late cytomegalovirus (CMV) disease is poorly defined.
G
anciclovir effectively prevents cytomegalovirus (CMV) disease during the first 3 months after hematopoietic cell transplantation (HCT) when given prophylactically at engraftment or preemptively for pp65 antigenemia or detection of CMV DNA by polymerase chain reaction (PCR). It improves survival in selected high-risk patients (1, 2) . However, most cases of CMV disease now occur after withdrawal of ganciclovir (3) (4) (5) (6) (7) , most frequently between 100 and 270 days after transplantation (3) . In the absence of preventive strategies, both late CMV infection and disease are independent predictors for death after HCT (3) . Although preemptive therapy based on virologic surveillance is the most commonly used strategy to prevent CMV disease during the first 3 months after HCT (8) , maintaining surveillance is often difficult late after HCT because patients often return to remote locations and regular blood draws may be difficult to perform. The rationale for studying a prophylactic approach is supported by the observation that even asymptomatic CMV infection is associated with increased mortality rates, suggesting a role of indirect effects of CMV in the late period (3) . However, the benefits of ganciclovir and valganciclovir prophylaxis are theoretically counterbalanced by their most common toxicity (neutropenia), which is also independently associated with death early after HCT (9, 10) .
METHODS

Design
This was an investigator-initiated, multicenter, double-blind, placebo-controlled, randomized clinical trial. The Fred Hutchinson Cancer Research Center (FHCRC) held the Investigational New Drug application and served as the coordinating center. Patients were randomly assigned to receive valganciclovir (900 mg once per day) or matching placebo (Appendix Figure  1 , available at www.annals.org) between 1999 and 2008. Study patients, study personnel, and all clinical personnel were blinded. The study drug was withdrawn when CMV viral load was greater than 1000 copies/mL or greater than 5 times the baseline value, and preemptive therapy was started with intravenous ganciclovir (5 mg/kg twice daily) or valganciclovir (900 mg twice daily); foscarnet (90 mg/kg twice daily) was used instead if indicated due to neutropenia. All doses were adjusted to the creatinine clearance as per manufacturer recommendations. Weekly study samples were mailed to
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Seattle, Washington, and tested at the University of Washington clinical laboratories. Cytomegalovirus and chemistry testing results were made available in real time to study sites to allow initiation of open-label preemptive treatment of CMV disease, dose adjustment, drug withdrawal, or start of hematopoietic growth factors as prespecified in the protocol. The study drug was held and growth factors were started if the absolute neutrophil count decreased to less than 1.0 × 10 9 cells/L.
A CMV DNA level greater than 1000 copies/mL or consecutive positive results with increasing levels was used to withdraw the study drug and start preemptive treatment with open-label intravenous ganciclovir treatment. The protocol was amended halfway through the study to make valganciclovir open-label treatment available to patients for breakthrough preemptive therapy (instead of requiring intravenous treatment) and to formally include granulocyte colony-stimulating factor (G-CSF) treatment of neutropenia at an absolute neutrophil count of 1.0 × 10 9 cells/L.
Setting and Patients
Allogeneic HCT recipients aged 16 years or older who were seropositive for CMV before transplant or had a seropositive donor were eligible. Seropositive recipients had to have either CMV infection with appropriate treatment course before random assignment; a history of graft-versus-host disease (GVHD) after transplantation requiring treatment with systemic corticosteroids at doses greater than 0.5 mg/kg at any time before enrollment; chronic, clinically extensive GVHD requiring treatment with corticosteroids; or receipt of ganciclovir, valganciclovir, foscarnet, or cidofovir prophylaxis between engraftment and random assignment. Seronegative recipients with seropositive donors had to have a CMV infection with appropriate treatment course before random assignment. A complete listing of inclusion and exclusion criteria is shown in Appendix 1 (available at www.annals.org).
Randomization and Interventions
Randomization occurred once patients were identified as eligible for the study at a median of 97 and 98 days after HCT for the valganciclovir and placebo groups, respectively ( Table 1) . We used an adaptive randomization scheme implemented using a statistical program written by an FHCRC statistician and run by staff of the FHCRC protocol office. Randomization was stratified by study site, previous neutropenia (presence or absence of absolute neutrophil count <1.0 × 10 9 cells/L after initial engraftment), and presence or absence of refractory GVHD (requiring secondary therapy) at study enrollment (11, 12) .
Outcomes and Follow-up
The primary end point was a composite outcome consisting of CMV disease, invasive bacterial or fungal infections, or death (whichever occurred first), thereby assessing the net effect of the strategy, including consequences of neutropenia (9) . Because most cases of late CMV disease occur between 4 and 9 months after HCT (3-5), the primary study period for the intervention was until 270 days after HCT. Follow-up was extended until 640 days after HCT for CMV disease, death, and CMV-specific immune reconstitution. Secondary end points were CMV disease (defined as per international guidelines [13] ), death, invasive bacterial or fungal infections (defined as published [1, 14] ) (Appendix 2, available at www.annals.org), use of invasive tests (such as endoscopy procedures, including bronchoscopies), number of days alive without hospitalization during the active study period, treatment-emergent ganciclovir resistance, quality of life (QOL) as determined by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-30) (15) , herpesvirus-specific T-cell function, and adverse events (clinical and laboratory).
Laboratory Methods
Cytomegalovirus viral load was determined at the University of Washington using a validated laboratorydeveloped quantitative PCR method; the assay's conversion factor to IU/mL is 1.0 (16). Cytomegalovirusspecific T-cell function was determined by a multicolor flow cytometry assay designed to detect polyfunctional CD4+ and CD8+ T cells (17, 18) . Ganciclovir resistance was examined by testing patients with persistent or increasing viral load (>1000 copies/mL) while receiving open-label treatment for mutations in the UL97 gene, using a rapid PCR-and sequencing-based assay as previously described (19) . Safety laboratory testing (serum creatinine, alanine aminotransferase, blood differential, and platelet count) was done using established meth-
EDITORS' NOTES Context
Cytomegalovirus (CMV) disease is a late complication of allogeneic hematopoietic cell transplantation (HCT).
Contribution
In a multicenter, randomized, double-blind trial of patients who had HCT and were at high risk for late CMV disease, continuous valganciclovir prophylaxis was compared with a strategy of CMV polymerase chain reaction-guided preemptive therapy with valganciclovir and ganciclovir. These 2 approaches did not differ in the occurrence of death, CMV disease, or other invasive fungal infections. Safety was similar.
Caution
More patients who received continuous valganciclovir required hematopoietic growth factors.
Implication
Both continuous valganciclovir prophylaxis and CMV polymerase chain reaction-guided preemptive therapy are viable alternatives to prevent late CMV disease after HCT.
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Statistical Analysis
The frequency of the primary composite end point was 53% in our previous cohort (3). Our study was designed to test the superiority of the prophylactic strategy. To demonstrate a 45% reduction of the primary end point (which was deemed clinically meaningful), 184 randomly assigned patients (92 per treatment group) were needed to provide approximately 87% power (allowing for 1 interim analysis at the 0.005 ␣ level and a final analysis at the 0.048 ␣ level). All statistical tests were 2-sided.
All patients who were randomly assigned and received at least 1 dose of study medication were included in the analysis. Descriptive statistics were used to summarize demographic and baseline characteristics of study patients. Comparisons between study groups of time to the primary end point from HCT to 270 days after HCT were evaluated using Cox regression models adjusted for the stratification factors of neutropenia presence before random assignment or absence of an absolute neutrophil count less than 1.0 × 10 9 cells/L after initial engraftment and study site (FHCRC vs. other site). The number of patients with previous refractory GVHD was not sufficient to include this stratification factor. Secondary time-to-event outcomes were evaluated similarly; some outcomes were evaluated to 640 days, as noted in Table 2 . Cumulative incidence curves were also used to evaluate time-to-event outcomes, with death as a competing risk for all outcomes except mortality (20) . All time-to-event analyses were censored at the time of last contact in the absence of a competing risk or event of interest. Absolute differences and associated 95% CIs were evaluated using Late CMV Prevention After HCT ORIGINAL RESEARCH standard methods for risk differences for proportions (21), but SEs of cumulative incidence were used to construct CIs for cumulative incidence. Differences in medians with CIs were evaluated using Hodges-Lehmann estimation (22) . Other secondary outcomes were compared between study groups with chi-square, Fisher exact, or Wilcoxon rank-sum tests, as appropriate. Subset analyses of efficacy and neutropenia end points were done post hoc and displayed in forest plots. These were carried out within strata defined by unique categories of each of the following variables: sex, CMVseropositive recipient or donor status, HCT conditioning type, donor relation, underlying disease risk, cell source, neutropenia before random assignment, absence of refractory GVHD before random assignment, and random assignment before or after 1 January 2004. Missing data in our study were minimal and only present to any extent for QOL data at 6 and 9 months, when it was 78% and 79% complete, respectively. The multiple imputation method was used to generate 10 replicate values for each missing QOL measurement at each time point using the method of partial mean matching (23) using study group and baseline covariates, including baseline QOL for the latter time points, for the prediction model. Reported analytic results were obtained by combining analysis results across imputed data sets with standard formulas (24) . Linear regression models were used to compare QOL between study groups at each time point. An interim analysis was done and reviewed by the independent data safety monitoring board after 92 patients (50%) had completed 90 days of study. Toxicity and the primary end points and their components were reviewed. The study was permitted to continue.
All statistical analyses were performed using SAS, version 9.3 (SAS Institute).
Role of the Funding Source
Roche Laboratories provided the study drug and placebo and funded the clinical trial but had no role in the design or conduct of the study, analysis of the data, or decision to submit the manuscript for publication. All analyses (statistical and laboratory) were done at FH-CRC, and investigators had full access to the data and data analysis. Partial support was obtained by the National Institutes of Health for resistance and T-cell immunity testing. 
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RESULTS
Study Population
The study flow diagram is shown in Figure 1 . Table  1 shows balanced clinical characteristics between the study groups.
Primary End Point
There were no statistically significant differences between the groups for the composite end point (death or CMV disease or other serious invasive infections by 270 days after HCT) or its individual components (Figure 2 and Tables 1 and 2). Analyses of the primary end point at 270 and 640 days were done within subsets of the study population (Appendix Figure 2 , available at www.annals.org), which also did not suggest differential treatment effects within specific subgroups.
Secondary Efficacy End Points
CMV End Points
The cumulative incidence of initiation of preemptive therapy (CMV DNA level >1000 copies/mL of plasma or increasing CMV DNA levels of >5 times the baseline level), any CMV DNA detection, and any PCR positivity and CMV DNA level greater than 10 000 copies/mL are shown in Tables 2 and 3 and Figure 3 . There was significantly more CMV infection in the placebo group. The hazards of CMV disease did not differ between the groups throughout the study ( Table 2) ; there was also no apparent difference in the clinical manifestations of CMV disease (Appendix Table 1 , available at www.annals.org). The 6-week and 6-month mortality rates after CMV disease did not differ between patients who developed CMV disease in the valganciclovir and placebo-preemptive therapy groups (Appendix Table 1 ).
Herpes Simplex Virus and Varicella Zoster Virus
Hazards of herpes simplex virus (HSV) and varicella zoster virus (VZV) infections between randomization and 640 days did not significantly differ between groups ( Table 2 ). There were no cases of HSV infection in the valganciclovir group and 1 case in the placebo group before 270 days; by 640 days, 7 cases (7.4%) of HSV occurred in the valganciclovir group versus 2 (2.2%) in the placebo group. There was 1 case of VZV infection in each group (at 383 days in the valganciclovir group and 224 days in the placebo group). 
Invasive Bacterial and Fungal Infections
The incidence of invasive bacterial and fungal infections between randomization and 270 and 640 days after HCT did not differ ( Table 2) .
Survival
Death from all causes was compared between valganciclovir and placebo groups (270 and 640 days) and did not significantly differ (Figure 2) .
Safety End Points
Adverse Events and Serious Adverse Events
The number of patients with adverse events (AEs) and serious AEs (Appendix Table 2 , available at www .annals.org) did not differ. More patients with drugrelated grade 2 AEs were reported in the valganciclovir group, which was driven by neutropenia (40% in the placebo group vs. 55% in the valganciclovir group; P = 0.043), but there were no differences between the groups at grade 3 or greater levels (data not shown). There was no statistically significant difference between the groups for the proportion of patients with any of the AE categories by organ system, with the exception of grade 2 events before 270 days in the "blood and marrow category," where the difference approached statistical significance (46% in the placebo group and 53% in the valganciclovir group; P = 0.052). The proportion of patients with gastrointestinal or renal AEs did not differ between groups.
Hematologic Variables
Neutropenia was analyzed at different levels ( Table  2 ). The analysis was done during the double-blind phase of the study drug and for the entire active treatment period (randomization until 270 days after Left. Primary end point. Right. Overall survival. 
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Late CMV Prevention After HCT transplantation). There was more neutropenia at the absolute neutrophil count of 1.0 × 10 9 cells/L levels in valganciclovir recipients during the double-blind phase; this trend did not persist at more severe levels of neutropenia (absolute neutrophil count, <0.5 × 10 9 cells/L). More patients received G-CSF in the valganciclovir group (Table 3) . In a post hoc analysis to determine whether neutropenia was more common in specific risk groups, no statistically significant predisposition to neutropenia at moderate and severe levels of neutropenia was found, with the exception of donor status (Appendix Figure 3, available at www.annals.org) . Use of preemptive G-CSF (introduced for patients randomly assigned after 1 January 2004) seemed to eliminate the difference in severe neutropenia (<0.5 × 10 9 cells/L) between the groups. There was no difference in thrombocytopenia or in the requirement for blood product support between the groups ( Table 3) .
Resource Utilization
We compared several variables of resource utilization between groups. None of the variables significantly differed, with the exception of G-CSF use ( Table 3) .
Resistance
Patients who met the criteria for resistance testing had both the first and last plasma sample analyzed (24 patients: 6 assigned to valganciclovir and 18 to placebo). No UL97 mutations that were associated with phenotypic resistance confirmed by marker transfer were found (23).
Immune Reconstitution
Virus-specific T-cell immunity was assessed at baseline and longitudinally. No differences were found between the study groups for lymphoproliferative responses to CMV, HSV, or VZV (Figure 4) or for interferon-␥ CD4+ intracellular cytokine responses (data not shown); a sensitivity analysis using greater than 0.1% as the threshold for a positive response also did not show differences between the groups.
Longitudinal testing of polyfunctional intracellular cytokines was done in a subset of patients who had complete follow-up. Overall functionality (data not shown) and polyfunctionality did not differ among patients who had positive CB8+ interferon-␥ ( Figure 4 ) and interleukin-2 responses (data not shown).
Quality of Life
Quality of life was assessed at baseline, 180 days, and 270 days after transplantation using the validated EORTC QLQ-30 (version 3). Overall, there were no differences in QOL variables between the groups. There was an imbalance in the category "emotional functioning" at baseline, and this difference persisted at the final study evaluation (Appendix Table 3 , available at www.annals.org).
DISCUSSION
Our study did not show superiority of valganciclovir prophylaxis against prevention of late survival without CMV disease and invasive infection after HCT when compared with PCR-guided CMV preemptive therapy. Both strategies seemed to perform similarly well in preventing CMV disease during the active study period and for 1 year thereafter and seemed to perform significantly better than historical cohorts that used no prevention strategies (4, 5, 7, 25, 26). Valganciclovir CMV = cytomegalovirus; PCR = polymerase chain reaction. Top. >1000 copies/mL of CMV DNA or 5-fold increase over baseline (study drug withdrawal) (P = 0.004). Middle. Any PCR positivity (P = 0.005). Bottom. >10 000 copies/mL of CMV DNA (P = 0.025).
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prophylaxis was associated with similar rates of hematologic and other toxicities compared with PCR-guided preemptive therapy. No differences were seen between the groups with regard to other herpesvirus infection, the tempo of T-cell immune reconstitution, or the rate of UL97 mutations. We chose the primary composite end point of survival without CMV disease and invasive infection to capture both the putative benefits and risks for valganciclovir prophylaxis. There was no statistically significant difference in the composite end point between groups (Tables 2 and 3) .
One possible reason that valganciclovir prophylaxis did not improve outcomes compared with preemptive therapy is the excellent performance of the preemptive strategy. Prevention of CMV disease with PCR-guided preemptive therapy was near complete, with a rate of 2% at the end of the active study period at 270 days. A similar effectiveness of anti-CMV preemptive therapy was reported in a recent multicenter clinical trial during the first 3 months after HCT (27) . Preemptive therapy seemed to work well even when administered to patients who live far away from comprehensive cancer centers, as in this clinical study 
Late CMV Prevention After HCT where laboratory testing was done by means of overnight shipment and clinical feedback was provided via telephone. However, this strategy is resource-intensive: In our study, virologic testing was closely monitored by dedicated study personnel, and study patients were contacted when a sample did not arrive. Our monitoring procedures were primarily designed to ensure regular safety monitoring because one half of the patients were receiving valganciclovir prophylaxis; however, it also proved to be an effective approach for CMV monitoring. Whether high adherence to weekly testing can be replicated in usual clinical practice is unknown, but limited evidence exists (28). One concern with prolonged valganciclovir prophylaxis in HCT recipients is hematotoxicity (2, 29, 30). We found relatively high rates of neutropenia in both groups. Although there was more neutropenia at an absolute neutrophil count less than 1.0 × 10 9 cells/L in prophylaxis recipients, there were essentially similar rates of severe neutropenia (absolute neutrophil count, <0.5 × 10 9 cells/L) in both groups. We attribute these similar rates to the routine preemptive administration of G-CSF in the second half of the study. Although this protocol change resulted in increased use of G-CSF in the valganciclovir group, we achieved the desired effect of similar rates of invasive bacterial and fungal infections between the groups ( Table 3) .
A delay of recovery of T-cell immunity has been seen with effective long-term viral suppression (31, 32), and a delay in T-cell recovery was associated with prolonged risk periods for herpesvirus complications (3, 4, 33) . However, the association between antiviral prophylaxis and delayed immune reconstitution is inconsistent (7, 34) . Our study examined T-cell immunity to CMV, HSV, and VZV longitudinally and found no difference in the immune reconstitution rates throughout the study period. Thus, extended valganciclovir prophylaxis did not affect virus-specific T-cell recovery during or after drug administration.
The study also examined several other clinically relevant end points ( Table 3) . Both strategies showed similar outcomes using all of these measures. We also did post hoc subset analyses to determine whether efficacy and toxicity outcomes were equally distributed between groups within patient subgroups. We found no differences between study groups in terms of efficacy or toxicity within subgroups (Appendix Figures 2 and  3) .
To our knowledge, this is the first study that attempted and successfully completed real-time management of CMV preemptive treatment and toxicity management across 36 U.S. states. However, because of the complexity of the design and study requirements, it took 8 years to complete the trial.
One limitation of the study is that, similar to a recent phase III maribavir trial (27) , patients at highest risk for CMV complications (that is, patients with persistent viral replication during the enrollment window) were excluded. Another limitation is that no formal costeffectiveness analysis was done.
In conclusion, valganciclovir prophylaxis was not superior in reducing the composite end point of CMV disease, invasive bacterial and fungal disease, and death when compared with PCR-guided preemptive therapy. Both CMV prevention strategies used in this study proved to be extremely effective, and our trial extends the evidence base for management of patients at high risk for late CMV disease. Tissue documented: Clinical signs and symptoms compatible with invasive yeast infection and a positive culture from a normally sterile site with histologic evidence of tissue invasion (definite) or a positive culture from a sterile site without histologic evidence of invasion (probable).
Bacteremia
Any single blood culture that is positive for bacterial pathogens consistent with a serious bloodstream infection. Results will be analyzed in groups (gramnegative, gram-positive with and without coagulasenegative staphylococci, and non-JK Corynebacteria). Urinary tract infections will not be captured.
Invasive Bacterial Tissue Infection
Clinical signs and symptoms compatible with disease (sinusitis, pneumonia, and intraabdominal abscess) and radiographic evidence of disease and pure or predominant culture or pathogen detection from a sterile site biopsy. Pathogen detection in respiratory secretion or sinus aspirates or cerebrospinal fluid specimens will be considered if they are predominant and compatible with the clinical picture. Typhlitis (neutropenic enterocolitis) is defined as clinical signs and symptoms compatible with disease and typical radiographic evidence of disease with or without culture confirmation.
Infection Recurrence
Recurrent infections, in contradistinction to new infectious episodes, are defined as follows: a. Mold infections diagnosed less than 6 weeks after previous mold infection with same mold species b. Yeast infections diagnosed less than 6 weeks after previous yeast infection with same yeast species c. Bacterial infections diagnosed less than 3 weeks after previous bacterial infection with same bacterial species d. Viral infections diagnosed less than 3 weeks after previous viral infection with same viral species. subsets at 270 days (top) and 640 days (bottom). QOL = quality of life. * Includes imputed data for 9 patients at period 1, 35 at period 2, and 29 at period 3; 184, 166, and 155 patients were alive and eligible for assessment at periods 1, 2 and 3, respectively. Two patients at period 2 and 3 at period 3 were not imputed because of missing the period 1 QOL assessment for the imputation model. † 95 patients in the valganciclovir group and 89 patients in the placebo group. ‡ 84 patients in the valganciclovir group and 80 patients in the placebo group. § 75 patients in the valganciclovir group and 77 patients in the placebo group.
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